The Indianapolis-based drugmaker will work to support UNICEF’s efforts to strengthen primary health care systems to prevent, ...

Eli Lilly launches Lormalzi in India, a once-monthly Alzheimer's therapy for mild impairment. It targets amyloid plaques to ...

Eli Lilly has made a six-year, $50 million commitment to UNICEF USA to support efforts to improve the prevention, detection ...

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

In this episode of Adspeak by ADWEEK, chief brand and community officer Jenny Rooney speaks with Jason White, board member at ...

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player ...

The S&P 500, which is a leading benchmark of the US stock market performance, has surged by around 8.7% since the beginning ...

Metabolism as a Growth Driver No company currently demonstrates more impressively than Eli Lilly just how efficient it can be ...

Biogen Inc. said it will continue development of its experimental Alzheimer’s drug after getting promising though not ...

WEIGHT loss jabs can halve the number of employee sick days, a study has found. The results are a boost to NHS plans to roll ...

Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 2026 Annual Meeting along with initial ...

Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.